Patients Coming Off Slimming Medications Regain Weight at a Quadrupled Rate Than Those on Conventional Diets

Fresh analysis reveals that people who stop using popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who end conventional lifestyle regimens.

Published data in a leading medical journal points out that while overweight individuals frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.

"Individuals buying such medications should be cognizant of the potential of fast rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.

This pace of regain implies a reversion to pre-treatment weight within about 18 months.

Analyzing Therapies

The analysis, which looked at dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with conventional dieting.

The team emphasize that individuals who lose weight through dieting typically see a slower creep back—approximately 0.1 kg a month—once they finish.

Understanding the Rapid Rebound

Doctors propose the way of the drugs accounts for the accelerated regain.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Sustained high doses of GLP-1 levels several times higher than the body's typical production may cause the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this medication leads to appetite is uncontrolled, making binge eating much more probable."

An Ongoing Condition?

Health authorities advise the injections for people with weight-linked medical conditions, alongside prescribed lifestyle changes.

Professionals contend that, given the likelihood of relapse, the treatment might need to be ongoing.

This view is reinforced by drug manufacturers, who say that the findings "emphasize the persistent character of excess weight," akin to managing diseases like diabetes.

Patient Accounts

Users who have discontinued the jabs describe a sudden resurgence of cravings.

"It was like something that goes on and I was suddenly ravenous," recalled a patient.

The struggle is worsened if individuals have not established sustainable dietary or behavioural changes during treatment.

Widespread Adoption

Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.

• Use is higher among females than men.
• The 40s and 50s demographic shows the highest level of interest.
• Many obtain the drugs through private healthcare rather than the NHS.

Finally, experts stress that while the jabs are potent agents for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated lifestyle management.